Global Organ Transplantation Demand Will Expand Market Opportunity

Key Takeaways

• Expansion into new markets, improved reimbursement, and strong transplant demand are driving significant sales and margin growth for IDEFIRIX and other biologics.
  
• Advancing pipeline diversification and upcoming clinical readouts reduce single-product dependency, positioning for multi-asset growth and enhanced long-term earnings potential.
  
• Heavy reliance on one drug, regulatory risks, and volatile policy environments threaten both near
• and long-term revenue stability and complicate future financing and growth prospects.

Catalysts

A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.

• Strong global growth in organ transplantation and expanding patient pools due to aging populations and chronic disease is expected to drive sustained demand for desensitization solutions like IDEFIRIX, supporting long-term revenue acceleration as more patients require transplants.
  
• Improving healthcare access and reimbursement in both developed and emerging markets, coupled with recent launches in new territories (Australia, Switzerland) and expanded reimbursement (now in 20 countries), increases patient access to high-cost biologics and has already led to a 76% YoY sales increase, strengthening top-line growth and gross margins.
  
• Imminent Phase III readouts (ConfIdeS for kidney transplant and GOOD-IDES-02 for anti-GBM) and broadening regulatory submissions/approvals, particularly the planned U.S. BLA, could substantially expand addressable markets and catalyze step-changes in earnings and cash flow if successful.
  
• Ongoing pipeline diversification (gene therapy pre-treatment, Guillain-Barre, autoimmune, and further indications under review) positions Hansa for multi-asset clinical success, reducing reliance on a single product and offering "multiple shots on goal," enhancing long-term revenue potential and improving risk-adjusted pipeline valuation.
  
• Operational restructuring yielding >SEK 60M in annual cost savings, together with increased efficiency and gross margin improvement (from 35% to 66% YoY), sets the stage for potential positive operating leverage and improved net margins as revenues ramp from both new and existing markets.

Hansa Biopharma Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Hansa Biopharma's revenue will grow by 76.8% annually over the next 3 years.
• Analysts are not forecasting that Hansa Biopharma will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Hansa Biopharma's profit margin will increase from -240.3% to the average GB Biotechs industry of 20.1% in 3 years.
• If Hansa Biopharma's profit margin were to converge on the industry average, you could expect earnings to reach SEK 246.8 million (and earnings per share of SEK 1.98) by about April 2029, up from -SEK 534.1 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 48.3x on those 2029 earnings, up from -6.3x today. This future PE is greater than the current PE for the GB Biotechs industry at 18.6x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.76%, as per the Simply Wall St company report.

Risks

• Germany's suspension of the Eurotransplant prioritization program for highly sensitized kidney transplant patients has already caused a near-term negative impact on revenues, and ongoing evaluation of "health equity" in transplantation could lead other regions to reduce use or access, creating risk of reduced or stagnant long-term revenue in key European markets.
  
• The company's financial sustainability is fragile, relying on recent capital raises and debt restructuring to extend its cash runway only into early Q2 2026; failure of upcoming pivotal trial readouts or regulatory setbacks could limit new financing options, drive further dilution, or precipitate severe cuts, depressing net margins and share price.
  
• Hansa remains highly dependent on IDEFIRIX (imlifidase) for the vast majority of its revenues and margin improvements; slow diversification of the pipeline or commercial delays for additional indications would leave the company vulnerable to competitive pressures and impede sustainable earnings growth.
  
• Fluctuating and unpredictable organ allocation policies, as well as complex, country-specific organ systems, present ongoing commercial and operational risks-this variability makes quarter-to-quarter revenue growth volatile and hampers the ability to reliably forecast long-term top-line results.
  
• Higher R&D risk remains due to pending clinical trial outcomes for both kidney transplant and new indications (e.g., GOOD-IDES-02, gene therapy collaborations); any negative or inconclusive data could not only impair future revenues but also undermine the company's perceived value proposition, making it harder to secure future investor or partner support and reducing earnings potential.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK80.83 for Hansa Biopharma based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK103.0, and the most bearish reporting a price target of just SEK35.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK1.2 billion, earnings will come to SEK246.8 million, and it would be trading on a PE ratio of 48.3x, assuming you use a discount rate of 5.8%.
• Given the current share price of SEK33.0, the analyst price target of SEK80.83 is 59.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.